News Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Real-time Estimate Cboe BZX Other stock markets 02:22:02 2024-04-18 pm EDT			5-day change	1st Jan Change
1.435 ^USD	+2.50%		-57.40%	-85.32%

03:14pm	Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	MT
02:23pm	Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	09:14am	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	08:23am	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	Apr. 17	MT
Sector Update: Health Care Stocks Higher Late Afternoon	Apr. 16	MT
Sector Update: Health Care	Apr. 16	MT
Pacific Biosciences of California Q1 Revenue Expected to Be Flat Year Over Year; Guidance Lowered; Shares Sink	Apr. 16	MT
PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance	Apr. 16	PR
Pacific Biosciences of California, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024	Apr. 16	CI
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	Apr. 10	MT
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes	Mar. 27	PR
Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes	Mar. 27	CI
PacBio Grants Equity Incentive Award to New Employee	Mar. 22	PR
Transcript : Pacific Biosciences of California, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	Mar. 12
PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions	Mar. 12	PR
PacBio Announces PureTarget Repeat Expansion Panel, Expanding Its Portfolio of End-To-End Clinical Research Solutions	Mar. 12	CI
PacBio to Present at Upcoming Investor Conferences	Feb. 26	PR
Federal Circuit Affirms Claim Construction And How It Applies	Feb. 20	AQ
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	Feb. 16	MT
Pacific Biosciences of California Q4 Non-GAAP Loss Narrows, Revenue Rises; Shares Drop After Hours	Feb. 15	MT
Transcript : Pacific Biosciences of California, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Summary

Filters